Abeona Therapeutics (ABEO): Undervalued Pipeline - FBR
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
FBR Capital analyst, Vernon Bernadino, reiterated his Outperform rating on shares of Abeona Therapeutics (NASDAQ: ABEO) and believes recent activities by ABEO continue to show progress being made with its pipeline of rare disease candidate therapies and emerging preclinical assets. He thinks that ABEO's value could quickly accelerate in the coming months and reiterated his price target of $15.
EB-101 is a skin graft product that corrects for the absence of the Type VIII collagen gene (COL7A1), which is advancing with the announcement of the fifth patient enrolled in the Phase I/II clinical trial in recessive dystrophic epidermolysis bullosa (EB). The analyst thinks that this could be a major driver of ABEO's stock value.
Shares of Abeona Therapeutics closed at $5.78 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Abeona Therapeutics (ABEO) Granted U.S. FDA Fast Track Designation for ABO-102 in Sanfilippo Syndrome Type A
- Graphic Packaging (GPK) PT, Estimates Trimmed at Jefferies Post Q3
- Apple (AAPL) PT Raised to $135 at Brean Capital
Create E-mail Alert Related CategoriesAnalyst Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!